药物性肝损害的危险因素、诊断规范及停药标准

禹铮; 贾继东

doi:10.3969/j.issn.1001-5256.2013.09.010

药物性肝损害的危险因素、诊断规范及停药标准

DOI: 10.3969/j.issn.1001-5256.2013.09.010

禹铮,
贾继东

首都医科大学附属北京友谊医院肝病中心

详细信息

中图分类号: R595.3
计量
- 文章访问数: 3601
- HTML全文浏览量: 22
- PDF下载量: 864
- 被引次数: 0
出版历程
- 收稿日期: 2013-03-06
- 出版日期: 2013-09-20

Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury

Liver Research Center, Beijing Friendship Hospital, Capital Medical University

摘要

摘要: 药物性肝损害是指药物本身或其代谢产物引起的肝损害,是引起肝衰竭的重要原因之一。目前还缺乏有效的预测指标及诊疗手段。从易感因素、诊断和评价标准等方面对药物性肝损害进行介绍。了解药物性肝损害的最新进展,有利于及时发现药物性肝损害的易感患者;合理运用各种评价标准,有助于药物性肝损害的规范化诊疗。
- 肝炎,中毒性 /
- 危险因素 /
- 诊断
Abstract: Drug- induced liver injury ( DILI) is the liver injury caused by drugs or their metabolites, which is the common cause of live failure. Currently, there is still a lack of effective predictors and diagnostic and therapeutic methods for DILI. To gives an introduction to DILI from the aspects of risk factors, diagnostic criteria, causality assessment, etc. To understand the latest research progress in DILI can make for timely identification of patients susceptible to DILI; proper use of causality assessment can help standardize the diagnosis and treatment of DILI.
- hepatitis, toxic /
- risk factors /
- diagnostic

HTML全文

参考文献(33)

[1]LIU XY, CHEN J, WANG XX, et al.Etiological analysis of 3233patients with acute liver failure, subacute liver failure and acuteon-chronic liver failure[J].Clin Med Engineering, 2012, 19 (5) :823-825. (in Chinese) 刘晓燕, 陈婧, 王晓霞, 等.3233例急性、亚急性、慢加急性肝衰竭病因特点分析[J].临床医学工程, 2012, 19 (5) :823-825.

[2]LUCENA MI, ANDRADE RJ, KAPLOWITZ N, et al.Phenotypic characterization of idiosyncratic drug-induced liver injury:the influence of age and sex[J].Hepatology, 2009, 49 (6) :2001-2009.

[3]FERRAJOLO C, CAPUANO A, VERHAMME KM, et al.Druginduced hepatic injury in children:a case/non-case study of suspected adverse drug reactions in VigiBase[J].Br J Clin Pharmacol, 2010, 70 (5) :721-728.

[4]KUNST H, KHAN KS.Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection:a systematic review[J].Int J Tuberc Lung Dis, 2010, 14 (11) :1374-1381.

[5]KAPLOWITZ N, DELEVE LD.Drug-induced liver disease[M], 2nd edn, Informa, New York, 2007.

[6]CHALASANI N, BJORNSSON E.Risk factors for idiosyncratic drug-induced liver injury[J].Gastroenterology, 2010, 138 (7) :2246-2259.

[7]LAMMERT C, EINARSSON S, SAHA C, et al.Relationship between daily dose of oral medications and idiosyncraticdrug-induced liver injury:search for signals[J].Hepatology, 2008, 47 (6) :2003-2009.

[8]LAMMERT C, BJORNSSON E, NIKLASSON A, et al.Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events[J].Hepatology, 2010, 51 (2) :615-620.

[9]DALY AK, DONALDSON PT, BHATNAGAR P, et al.HLA-B*5701genotype is a major determinant of drug-induced liver injury due to flucloxacillin[J].Nat Genet, 2009, 41 (7) :816-819.

[10]YUAN J, GUO S, HALL D, et al.Toxicogenomics of nevirapineassociated cutaneous and hepatic adverse events among populations of African, Asian, and European descent[J].AIDS, 2011, 25 (10) :1271-1280.

[11]DONALDSON PT, DALY AK, HENDERSON J, et al.Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury[J].J Hepatol, 2010, 53 (6) :1049-1053.

[12]LUCENA MI, MOLOKHIA M, SHEN Y, et al.Susceptibility to amoxicillin-clavulanateinduced liver injury is influenced by multiple HLA class I and II alleles[J].Gastroenterology, 2011, 141 (1) :338-347.

[13]SINGER JB, LEWITZKY S, LEROY E, et al.A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury[J].Nat Genet, 2010, 42 (8) :711-714.

[14]McCORMACK M, ALFIREVIC A, BOURGEOIS S, et al.HLA-A*3101 and carbamazepineinduced hypersensitivity reactions in Europeans[J].N Engl J Med, 2011, 364 (12) :1134-1143.

[15]URBAN T, SHEN YF, CHALASANI NP, et al.A genome-wide association study identifies potential susceptibility loci for hepatotoxicity due to various drugs[J].Gastroenterology, 2011, 140 (Suppl1) :S886-S886.

[16]LEE SW, CHUNG LS, HUANG HH, et al.NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis[J].Int J Tuberc Lung Dis, 2010, 14 (5) :622-626.

[17]LYU X, TANG S, XIA Y, et al.NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population[J].Ann Hepatol, 2012, 11 (5) :700-707.

[18]DALY AK, DAY CP.Genetic association studies in drug-induced liver injury[J].Drug Metab Rev, 2012, 44 (1) :116-126.

[19]DENG R, YANG T, WANG Y, et al.CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury:a meta-analysis[J].Int J Tuberc Lung Dis, 2012, 16 (12) :1574-1581.

[20]CAI Y, YI J, ZHOU C, et al.Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury:a meta-analysis[J].PLoS One, 2012, 7 (10) :e47769.

[21]TANG N, DENG R, WANG Y, et al.GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury:a meta-analysis[J].Int J Tuberc Lung Dis, 2013, 17 (1) :17-25.

[22]LANG C, MEIER Y, STIEGER B, et al.Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury[J].Pharmacogenet Genomics, 2007, 17 (1) :47-60.

[23]URBAN TJ, SHEN Y, STOLZ A, et al.Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs[J].Pharmacogenet Genomics, 2012, 22 (11) :784-795.

[24]ANDRADE RJ, LUCENA MI, KAPLOWITZ N, et al.Outcome of acute idiosyncratic drug-induced liver injury:Long-term follow-up in a hepatotoxicity registry[J].Hepatology, 2006, 44 (6) :1581-1588.

[25]BORRAZ Y, FERNNDEZ MC, GARCA-MUOZ B, et al.Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI) ?[J].Hepatology, 2010, 52 (Suppl S1) :457a.

[26]ROCHON J, PROTIVA P, SEEFF LB, et al.Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury[J].Hepatology, 2008, 48 (4) :1175-1183.

[27]DAI WJ, LAI RT, WANG H, et al.The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury[J].J Clin Hepatol, 2012, 28 (10) :1058-1065. (in Chinese) 戴维佳, 赖荣陶, 王晖, 等.113例药物性肝损害临床特征及影响因素分析[J].临床肝胆病杂志, 2012, 28 (10) :1058-1065.

[28]WATANABE M, SHIBUYA A.Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales[J].Hepatol Res, 2004, 30 (3) :148-154.

[29]WATKINS PB.Biomarkers for the diagnosis and management of drug-induced liver injury[J].Semin Liver Dis, 2009, 29 (4) :393-399.

[30]ROCKEY DC, SEEFF LB, ROCHON J, et al.For the Drug-Induced Liver Injury Network:A structured assessment process to assign causality in drug induced liver injury[J].Hepatology, 2010, 51 (6) :2117-2126.

[31]TAJIRI K, SHIMIZU Y.Practical guidelines for diagnosis and early management of drug-induced liver injury[J].World J Gastroenterol, 2008, 14 (44) :6774-6785.

[32]BJRNSSON E, OLSSON R.Outcome and Prognostic Markers in Severe Drug-Induced Liver Disease[J].Hepatology, 2005, 42 (2) :481-489.

[33] U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.Guidance for Industry Drug-Induced Liver Injury:Premarketing Clinical Evaluation.http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

施引文献

资源附件(0)

访问统计